Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 1Dermatologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 4Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Hematologic Neoplasms 1Cholangiocarcinoma 1Camurati-Engelmann Syndrome 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Carboplatin 103Pemetrexed 96pembrolizumab 78Docetaxel 78Cisplatin 72Paclitaxel 70Erlotinib Hydrochloride 50Gemcitabine 48Radiotherapy 42Nivolumab 35Bevacizumab 35atezolizumab 24Radiosurgery 24durvalumab 19Cyclophosphamide 17130-nm albumin-bound paclitaxel 15Vinorelbine 14Taxes 14Radiation 14Etoposide 13Ipilimumab 12Albumin-Bound Paclitaxel 12avelumab 11Drug Therapy 10Cetuximab 10spartalizumab 9Sorafenib 9trametinib 8osimertinib 8capmatinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Non-Small-Cell Lung × bintrafusp alfa protein, human × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT04297748 2023-01-17

Bioimaging Study of 89Zr-M7824 in NSCLC

Olivia Newton-John Cancer Research Institute

Phase 1/2 Terminated
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡